Y.D. More Investments Ltd Trims Position in Kamada Ltd. (NASDAQ:KMDA)

Y.D. More Investments Ltd lowered its holdings in Kamada Ltd. (NASDAQ:KMDA) by 29.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 498,922 shares of the biotechnology company’s stock after selling 210,629 shares during the quarter. Y.D. More Investments Ltd’s holdings in Kamada were worth $3,025,000 as of its most recent SEC filing.

Separately, Public Employees Retirement System of Ohio purchased a new stake in shares of Kamada in the third quarter worth about $77,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Kamada in a report on Friday, January 10th.

Kamada Stock Performance

Shares of KMDA opened at $6.90 on Wednesday. The stock has a 50 day moving average price of $6.46 and a 200 day moving average price of $5.87. Kamada Ltd. has a one year low of $4.74 and a one year high of $8.00. The stock has a market capitalization of $396.61 million, a price-to-earnings ratio of 24.64, a PEG ratio of 0.85 and a beta of 0.99.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.